权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Calcineurin Inhibitor Minimization And Foxp3+ Tregs Post-Transplant

移植后钙调神经磷酸酶抑制剂最小化和 Foxp3 Tregs

基本信息

批准号：
7942967
负责人：
JOHN C BUCUVALAS
金额：
$ 48.1万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2012-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7942967
关键词：
Acetylation Adult Affect Allograft Tolerance Allografting Animals Autoimmunity CD4 Positive T Lymphocytes Calcineurin inhibitor Cardiovascular Diseases Cell physiology Cells Characteristics Chemicals Child Childhood Clinical Clonal Anergy Clonal Deletion Competence Cross-Sectional Studies Data Depressed mood Detection Development Disease Engraftment Epigenetic Process Event Face Functional disorder Funding Future Genetic Transcription Histone Acetylation Homeostasis Hospitals Human Immune Immune response Immunologic Monitoring Immunophenotyping Immunosuppression Immunosuppressive Agents Infection Kidney Kidney Transplantation Knowledge Life Liver Maintenance Malignant Neoplasms Messenger RNA Methylation Modeling Modification Molecular Target Morbidity - disease rate Mus Mutation Occupations Organ Transplantation Outcome Outpatients Patient Care Patients Pediatric Hospitals Pharmaceutical Preparations Phenotype Philadelphia Process Proteins Quality of life Regimen Regulatory T-Lymphocyte Reporting Research Personnel Research Support Risk Role Sampling Solid T-Cell Activation T-Lymphocyte Therapeutic immunosuppression Transplant Recipients Transplantation United States National Institutes of Health Withdrawal Work animal data base cardiovascular disorder risk economic impact experience follow-up forkhead protein graft function improved in vivo insight liver transplantation mortality operation peripheral blood public health relevance success

项目摘要

DESCRIPTION (provided by investigator): The Children's Hospital of Philadelphia (CHOP) contributes substantially to the local economy. In 2008, CHOP's operations created and supported over 16,882 jobs in the region, and CHOP's total economic impact was over $5.9 billion. Moreover, through a combination of private donations, NIH funding, and allocations from its hospital operations, CHOP receives more total research support than any other children's hospital in the US -- $180 million in fiscal year 2007-2008. The current application will create or retain 6 jobs. We wish to improve outcomes for transplant recipients by optimizing the current patient care. Solid organ transplant recipients face long-term morbidity and mortality from infections, renal dysfunction, malignancy and cardiovascular disease. This is of particular importance in children, who face a greater cumulative burden of life-long immunosuppression. Single centers have reported transplant recipients who appear functionally tolerant and require minimal or no immunosuppression. Initial data indicate immuno-suppression withdrawal in certain pediatric transplant recipients can be done safely and perhaps more successfully than in adults. To minimize risks associated with immunosuppression withdrawal or minimization, the definition of an immune phenotype that promotes allograft tolerance while maintaining immune competence is critical. We will focus on CD4+CD25+Foxp3+ T regulatory (Treg) cell function in pediatric liver and kidney transplant recipients since these cells are critical to induction and maintenance of allograft tolerance in various models. However, their role in clinical organ transplant recipients treated with regular "triple" immunosuppression is little understood. We hypothesize that use of CNI-based immunosuppression may impair the development and function of Foxp3+ Tregs; the functional effects may result from CNI differentially affecting two newly recognized chemical modifications of Foxp3, namely Foxp3 methylation and acetylation. In contrast, we hypothesize that transplant recipients on CNI-free immunosuppression will show increased Foxp3+ Treg numbers and/or function as a result of reversal of these epigenetic changes. Accordingly, we propose a cross-sectional study of renal or liver transplant recipients who are three or more year's post- transplant and have stable allograft function on CNI-based or CNI-free immunosuppression. We will use peripheral blood to assess whether CNI use depresses Foxp3+ Treg numbers and/or function, and whether CNI use promotes Foxp3 methylation and decreases Foxp3 and histone acetylation in transplant recipients? These studies will provide insights into the control of Foxp3+ Treg cell function, may suggest potential future molecular targets to modulate Foxp3 function in vivo, and will likely have major impact beyond the transplant field. We anticipate that they will also provide the key pilot data required for planned mechanistic studies in a follow-up multi-center trial of the effects of CNI minimization in pediatric transplant recipients. PUBLIC HEALTH RELEVANCE: Patients receiving organ transplants currently experience many years of good to excellent graft function and quality of life, but nevertheless these grafts typically do wear out and patients may experience additional serious diseases related to their maintenance immunosuppression. We hypothesize that certain immunosuppressive drugs widely used post-transplant may impair the functions of regulatory T cells that might otherwise promote engraftment with minimal or markedly reduced immunosuppression. Our studies of the effects of immunosuppression on regulatory T cells may revolutionize immunosuppressive therapy post- transplant and decrease patient morbidity and graft dysfunction long-term.